Previous Close | 23.04 |
Open | 22.97 |
Bid | 23.94 x 400 |
Ask | 24.16 x 200 |
Day's Range | 22.35 - 24.16 |
52 Week Range | 9.80 - 26.00 |
Volume | |
Avg. Volume | 324,809 |
Market Cap | 1.129B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.75 |
Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 34.67 |
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focu
Coliseum Capital increased its stake in boat maker MasterCraft. Insight Venture Partners sold shares of cybersecurity firm SentinelOne.
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminib ELVN-001 was well tolerated with no ≥ Grade 3 treatment-related non-hematologic toxicities reported Company to host virtual event with Key Opinion Leaders at 8:00 AM ET Today BOULDER, Colo.